Celgene and Vividion Therapeutics will jointly discover new medicines

| By | Celgene, Drug Development, R&D
0
201

Vividion Therapeutics, a biotechnology company using revolutionary proteomics and chemistry platforms, announced a strategic research collaboration with Celgene Corporation.

The multi-year collaboration is focused on the identification and development of unique small molecules against targets for a range of oncology, inflammatory and neurodegenerative indications. The collaboration is intended to advance new small molecules that function through the ubiquitin proteasome system, modulating specific protein levels for therapeutic benefit.

“Vividion has assembled a truly cutting-edge drug discovery platform that offers the opportunity to accelerate drug delivery in new and impactful ways by expanding the druggable proteome and addressing difficult targets,” said Rupert Vessey, President, Research and Early Development, Celgene. “This collaboration will provide both companies with the opportunity for a comprehensive, accelerated drug discovery approach to develop first-in-class therapeutics in areas with high potential impact for patients.”

The collaboration utilizes Vividion’s platform to identify ligands and discover drug candidates against a selected list of high value, difficult-to-drug targets. This platform makes accessible the broad set of proteins expressed in human cells and for the first time allows protein-drug interactions to be assessed with precision directly in native biological systems.

SOURCE: vividion
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.